About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER

ACP Issues Guideline on Erectile Dysfunction Drugs

by VR Sreeraman on October 21, 2009 at 12:15 PM
Font : A-A+

 ACP Issues Guideline on Erectile Dysfunction Drugs

The American College of Physicians (ACP) today issued recommendations for the treatment of erectile dysfunction (ED). ACP, the nation's largest medical specialty organization and second-largest physician group, strongly recommends that physicians initiate therapy with an oral phosphodiesterase type 5 (PDE-5) inhibitor in men who seek treatment for ED unless they have a contraindication to PDE-5 inhibitors, such as nitrate therapy.

As for which PDE-5 inhibitor to use, ACP recommends that physicians base the choice on the individual preferences of patients including ease of use, cost of medication, and adverse effects profile.


"The evidence is insufficient to compare the effectiveness or adverse effects of different PDE-5 inhibitors for the treatment of ED because there were only a few head-to-head trials," explained the lead author of the guideline, Amir Qaseem, MD, PhD, MHA, FACP, senior medical associate at the American College of Physicians.

The guideline authors analyzed evidence gathered from 130 randomized controlled trials that evaluated oral PDE-5 inhibitors alone or combined. Treatment with a PDE-5 inhibitor resulted in statistically significant and clinically relevant improvements in sexual intercourse and erectile function in patients with ED, regardless of the cause (e.g., diabetes, depression, prostate cancer) or baseline severity. The magnitude of benefit increased with severity of ED.

Overall, the evidence showed that PDE-5 inhibitors were relatively well-tolerated and were associated with mild or moderate adverse effects, such as headaches, flushing, upset stomach, and runny nose.

ACP does not recommend for or against routine hormonal blood tests or treatment in the management of patients with ED because the evidence is inconclusive about the effectiveness in patients with low testosterone levels. Physicians should individualize decisions to measure hormone levels based on the clinical symptoms (e.g., decreased libido, premature ejaculation, fatigue, etc.) and physical findings (for example, testicular atrophy, muscle atrophy) that suggest hormonal abnormality.

Source: Eurekalert
SRM

News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test your Knowledge on Heart Transplantation
Test Your Knowledge on Lung Transplantation
Baldness can be Cured and Prevented: let us see How!
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drugs In Impotence Drug Toxicity Erectile Dysfunction Priapism Signature Drug Toxicity Andropause / Male Menopause Premature Ejaculation Drugs Causing Sexual Problems Peyronie´s Disease Drugs for Erectile Dysfunction 

Most Popular on Medindia

Blood Donation - Recipients Nutam (400mg) (Piracetam) Iron Intake Calculator Calculate Ideal Weight for Infants Noscaphene (Noscapine) Accident and Trauma Care Pregnancy Confirmation Calculator Loram (2 mg) (Lorazepam) Daily Calorie Requirements Find a Hospital
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use

Consult an Expert